Literature DB >> 27381900

A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.

Mohamed H Shahin1, Yan Gong1, Caitrin W McDonough1, Daniel M Rotroff1, Amber L Beitelshees1, Timothy J Garrett1, John G Gums1, Alison Motsinger-Reif1, Arlene B Chapman1, Stephen T Turner1, Eric Boerwinkle1, Reginald F Frye1, Oliver Fiehn1, Rhonda M Cooper-DeHoff1, Rima Kaddurah-Daouk1, Julie A Johnson2.   

Abstract

Hydrochlorothiazide is among the most commonly prescribed antihypertensives; yet, <50% of hydrochlorothiazide-treated patients achieve blood pressure (BP) control. Herein, we integrated metabolomic and genomic profiles of hydrochlorothiazide-treated patients to identify novel genetic markers associated with hydrochlorothiazide BP response. The primary analysis included 228 white hypertensives treated with hydrochlorothiazide from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Genome-wide analysis was conducted using Illumina Omni 1 mol/L-Quad Chip, and untargeted metabolomics was performed on baseline fasting plasma samples using a gas chromatography-time-of-flight mass spectrometry platform. We found 13 metabolites significantly associated with hydrochlorothiazide systolic BP (SBP) and diastolic BP (DBP) responses (false discovery rate, <0.05). In addition, integrating genomic and metabolomic data revealed 3 polymorphisms (rs2727563 PRKAG2, rs12604940 DCC, and rs13262930 EPHX2) along with arachidonic acid, converging in the netrin signaling pathway (P=1×10(-5)), as potential markers, significantly influencing hydrochlorothiazide BP response. We successfully replicated the 3 genetic signals in 212 white hypertensives treated with hydrochlorothiazide and created a response score by summing their BP-lowering alleles. We found patients carrying 1 response allele had a significantly lower response than carriers of 6 alleles (∆SBP/∆DBP: -1.5/1.2 versus -16.3/-10.4 mm Hg, respectively, SBP score, P=1×10(-8) and DBP score, P=3×10(-9)). This score explained 11.3% and 11.9% of the variability in hydrochlorothiazide SBP and DBP responses, respectively, and was further validated in another independent study of 196 whites treated with hydrochlorothiazide (DBP score, P=0.03; SBP score, P=0.07). This study suggests that PRKAG2, DCC, and EPHX2 might be important determinants of hydrochlorothiazide BP response.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  genome-wide association study; hydrochlorothiazide; hypertension; metabolomics; pharmacogenetics

Mesh:

Substances:

Year:  2016        PMID: 27381900      PMCID: PMC4982802          DOI: 10.1161/HYPERTENSIONAHA.116.07328

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  33 in total

1.  Pharmacogenomics of antihypertensive drugs: past, present and future.

Authors:  Julie A Johnson
Journal:  Pharmacogenomics       Date:  2010-04       Impact factor: 2.533

Review 2.  Netrins: versatile extracellular cues with diverse functions.

Authors:  Karen Lai Wing Sun; James P Correia; Timothy E Kennedy
Journal:  Development       Date:  2011-06       Impact factor: 6.868

3.  Netrin requires focal adhesion kinase and Src family kinases for axon outgrowth and attraction.

Authors:  Guofa Liu; Hilary Beggs; Claudia Jürgensen; Hwan-Tae Park; Hao Tang; Jessica Gorski; Kevin R Jones; Louis F Reichardt; Jane Wu; Yi Rao
Journal:  Nat Neurosci       Date:  2004-10-17       Impact factor: 24.884

4.  Netrin-1 controls sympathetic arterial innervation.

Authors:  Isabelle Brunet; Emma Gordon; Jinah Han; Brunella Cristofaro; Dong Broqueres-You; Chun Liu; Karine Bouvrée; Jiasheng Zhang; Raquel del Toro; Thomas Mathivet; Bruno Larrivée; Julia Jagu; Laurence Pibouin-Fragner; Luc Pardanaud; Maria J C Machado; Timothy E Kennedy; Zhen Zhuang; Michael Simons; Bernard I Levy; Marc Tessier-Lavigne; Almut Grenz; Holger Eltzschig; Anne Eichmann
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

5.  Protein kinase inhibitors and blood pressure control in spontaneously hypertensive rats.

Authors:  R A Buchholz; R L Dundore; W R Cumiskey; A L Harris; P J Silver
Journal:  Hypertension       Date:  1991-01       Impact factor: 10.190

Review 6.  Role of cytochrome P450 metabolites of arachidonic acid in hypertension.

Authors:  A Sarkis; R J Roman
Journal:  Curr Drug Metab       Date:  2004-06       Impact factor: 3.731

7.  Netrin-1 induces MMP-12-dependent E-cadherin degradation via the distinct activation of PKCα and FAK/Fyn in promoting mesenchymal stem cell motility.

Authors:  Sei-Jung Lee; Young Hyun Jung; Sang Yub Oh; Min Sik Yong; Jung Min Ryu; Ho Jae Han
Journal:  Stem Cells Dev       Date:  2014-06-16       Impact factor: 3.272

8.  Indapamide lowers blood pressure by increasing production of epoxyeicosatrienoic acids in the kidney.

Authors:  Fei Ma; Fan Lin; Chen Chen; Jennifer Cheng; Darryl C Zeldin; Yan Wang; Dao Wen Wang
Journal:  Mol Pharmacol       Date:  2013-05-31       Impact factor: 4.436

Review 9.  Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases.

Authors:  John D Imig; Bruce D Hammock
Journal:  Nat Rev Drug Discov       Date:  2009-10       Impact factor: 84.694

10.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

View more
  10 in total

Review 1.  Application of omics in hypertension and resistant hypertension.

Authors:  Jiuqi Guo; Xiaofan Guo; Yingxian Sun; Zhao Li; Pengyu Jia
Journal:  Hypertens Res       Date:  2022-03-09       Impact factor: 3.872

Review 2.  Genomic Determinants of Hypertension With a Focus on Metabolomics and the Gut Microbiome.

Authors:  Panayiotis Louca; Cristina Menni; Sandosh Padmanabhan
Journal:  Am J Hypertens       Date:  2020-05-21       Impact factor: 2.689

3.  Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.

Authors:  David E Lanfear; Jasmine A Luzum; Ruicong She; Hongsheng Gui; Mark P Donahue; Christopher M O'Connor; Kirkwood F Adams; Sandra Sanders-van Wijk; Nicole Zeld; Micha T Maeder; Hani N Sabbah; William E Kraus; Hans-Peter Brunner-LaRocca; Jia Li; L Keoki Williams
Journal:  Circ Heart Fail       Date:  2020-10-04       Impact factor: 8.790

4.  Pharmacogenomic studies of hypertension: paving the way for personalized antihypertensive treatment.

Authors:  Michael T Eadon; Sri H Kanuri; Arlene B Chapman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2018-01-03

5.  Metabolomics enables precision medicine: "A White Paper, Community Perspective".

Authors:  Richard D Beger; Warwick Dunn; Michael A Schmidt; Steven S Gross; Jennifer A Kirwan; Marta Cascante; Lorraine Brennan; David S Wishart; Matej Oresic; Thomas Hankemeier; David I Broadhurst; Andrew N Lane; Karsten Suhre; Gabi Kastenmüller; Susan J Sumner; Ines Thiele; Oliver Fiehn; Rima Kaddurah-Daouk
Journal:  Metabolomics       Date:  2016-09-02       Impact factor: 4.290

6.  Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.

Authors:  Mohamed H Shahin; Yan Gong; Reginald F Frye; Daniel M Rotroff; Amber L Beitelshees; Rebecca A Baillie; Arlene B Chapman; John G Gums; Stephen T Turner; Eric Boerwinkle; Alison Motsinger-Reif; Oliver Fiehn; Rhonda M Cooper-DeHoff; Xianlin Han; Rima Kaddurah-Daouk; Julie A Johnson
Journal:  J Am Heart Assoc       Date:  2017-12-29       Impact factor: 5.501

Review 7.  The Future of "Omics" in Hypertension.

Authors:  Gemma Currie; Christian Delles
Journal:  Can J Cardiol       Date:  2016-12-07       Impact factor: 5.223

8.  Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension.

Authors:  Timo P Hiltunen; Jenni M Rimpelä; Robert P Mohney; Steven M Stirdivant; Kimmo K Kontula
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

9.  The Effect of Genetically Guided Mathematical Prediction and the Blood Pressure Response to Pharmacotherapy in Hypertension Patients.

Authors:  Eli F Kelley; Thomas P Olson; Timothy B Curry; Ryan Sprissler; Eric M Snyder
Journal:  Clin Med Insights Cardiol       Date:  2019-05-03

Review 10.  An Overview of Metabolic Phenotyping in Blood Pressure Research.

Authors:  Ioanna Tzoulaki; Aikaterini Iliou; Emmanuel Mikros; Paul Elliott
Journal:  Curr Hypertens Rep       Date:  2018-07-10       Impact factor: 5.369

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.